Market closed
Upstream Bio, Inc./$UPB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Upstream Bio, Inc.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
Ticker
$UPB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
52
ISIN
US91678A1079
Website
UPB Metrics
BasicAdvanced
$465M
-
-$3.40
-
-
Price and volume
Market cap
$465M
52-week high
$10.50
52-week low
$5.14
Average daily volume
332K
Financial strength
Current ratio
47.433
Quick ratio
45.272
Long term debt to equity
0.223
Total debt to equity
0.381
Management effectiveness
Return on equity (TTM)
-28.62%
Valuation
Price to revenue (TTM)
99.112
Price to book
1.04
Price to tangible book (TTM)
1.04
Price to free cash flow (TTM)
-2.732
Growth
Revenue change (TTM)
-2.94%
Earnings per share change (TTM)
-76.64%
UPB News
AllArticlesVideos
Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs
GlobeNewsWire·2 weeks ago
Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent
Seeking Alpha·4 weeks ago
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Upstream Bio, Inc. stock?
Upstream Bio, Inc. (UPB) has a market cap of $465M as of May 17, 2025.
What is the P/E ratio for Upstream Bio, Inc. stock?
The price to earnings (P/E) ratio for Upstream Bio, Inc. (UPB) stock is 0 as of May 17, 2025.
Does Upstream Bio, Inc. stock pay dividends?
No, Upstream Bio, Inc. (UPB) stock does not pay dividends to its shareholders as of May 17, 2025.
When is the next Upstream Bio, Inc. dividend payment date?
Upstream Bio, Inc. (UPB) stock does not pay dividends to its shareholders.
What is the beta indicator for Upstream Bio, Inc.?
Upstream Bio, Inc. (UPB) does not currently have a Beta indicator.